Apollo Cancer Centres has become the first healthcare institution in India to introduce the Shield Multi-Cancer Detection (MCD) test, a blood-based screening tool designed to identify signals associated with multiple cancers through a single blood sample. The initiative marks a significant advancement in the country’s efforts to improve early cancer detection and expand access to precision oncology.
The launch follows a Memorandum of Understanding (MoU) signed between Apollo Cancer Centres and Zydus Lifesciences. Under an exclusive agreement with US-based precision oncology company Guardant Health, Zydus will bring the Shield MCD test to India, while Apollo Cancer Centres will offer the screening service through its network. The collaboration is expected to make advanced cancer screening more accessible to people at average risk of developing cancer, particularly those aged 45 years and above.
The Shield MCD test is a laboratory-developed, methylation-based blood test that can detect signals linked to 10 common cancers from a single blood draw. These include cancers of the bladder, breast, colorectal region, oesophagus, stomach, liver, lung, ovary, pancreas and prostate. Unlike conventional screening methods that typically focus on one type of cancer at a time, the new test is designed to screen for multiple cancers simultaneously, potentially enabling earlier diagnosis and timely medical intervention.
Early diagnosis remains one of the most effective strategies for improving cancer survival rates. Many cancers are detected only after symptoms appear, often when the disease has reached an advanced stage. Blood-based multi-cancer detection technologies aim to bridge this gap by identifying cancer-related biological signals before symptoms become evident, thereby increasing the chances of successful treatment and better patient outcomes.
Healthcare experts believe the introduction of the Shield MCD test could complement existing screening programmes rather than replace them. The technology is expected to serve as an additional screening option that encourages greater participation among individuals who may otherwise avoid conventional screening procedures. By offering a minimally invasive blood test, the initiative seeks to improve screening uptake and support earlier diagnosis across a wider population.
The partnership also reflects the growing adoption of precision medicine and advanced molecular diagnostics in India’s healthcare sector. With cancer cases continuing to rise, healthcare providers are increasingly investing in technologies that support personalised care, faster diagnosis and improved clinical outcomes. The availability of innovative blood-based screening tests is expected to strengthen the country’s cancer prevention and early detection ecosystem.
Apollo Cancer Centres said the introduction of the Shield Multi-Cancer Detection test reinforces its commitment to bringing cutting-edge oncology innovations to Indian patients. Through its collaboration with Zydus Lifesciences and Guardant Health, the organisation aims to expand access to advanced cancer screening technologies and support earlier intervention, ultimately improving survival rates and the overall quality of cancer care in the country.
